Centrum Medyczne Mbb-Med Marta Blach-Burek
- Address
- ul. Mieszka I 9C, 32-500 Chrzanow, Poland
Centrum Medyczne Mbb-Med Marta Blach-Burek - Cardiovascular Research Center
Centrum Medyczne Mbb-Med Marta Blach-Burek is a clinical research facility specializing in cardiovascular disease management and innovative therapeutic interventions. The center demonstrates particular expertise in conducting advanced Phase 3 clinical trials focused on preventing thromboembolic complications in patients with cardiac arrhythmias.
- Atrial fibrillation management and stroke prevention strategies
- Novel anticoagulation therapies and cardioembolic event prevention
- Comparative effectiveness studies of emerging cardiovascular medications
The center's research portfolio emphasizes the development of next-generation treatments for atrial fibrillation, with a focus on reducing the risk of stroke and systemic embolism. Through participation in multinational trials like LIBREXIA-AF, the facility contributes to advancing therapeutic options that may offer improved safety profiles and efficacy in preventing cardioembolic events in high-risk patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1IBSA Institut Biochimique SA1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Mbb-Med Marta Blach-Burek
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5 | Novo Nordisk A/S | Phase III | Not Recruiting | — | Dec 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.